

1 Tyler J. Woods (State Bar No. 232464)
 twoods@trialnewport.com
 2 Richard H. Hikida (State Bar No. 196149)
 rhikida@trialnewport.com
 3 Scott J. Ferrell (State Bar No. 202091)
 sferrell@trialnewport.com
 4 **NEWPORT TRIAL GROUP**
 A Professional Corporation
 5 4100 Newport Place, Suite 800
 Newport Beach, CA 92660
 6 Tel: (949) 706-6464
 Fax: (949) 706-6469

7 Attorneys for Plaintiffs

8
 9 **UNITED STATES DISTRICT COURT**
 10 **SOUTHERN DISTRICT OF CALIFORNIA**

11 THERMOLIFE INTERNATIONAL, LLC,
 and THE BOARD OF TRUSTEES OF
 12 THE LELAND STANFORD JUNIOR
 UNIVERSITY,
 13
 Plaintiffs,
 14
 vs.
 15
 SNAC SYSTEM, INC.,
 16
 Defendant

Case No. 13-cv-825 JLS (MDD)

**AMENDED COMPLAINT FOR
PATENT INFRINGEMENT**

JURY TRIAL DEMANDED

1 Plaintiffs ThermoLife International, LLC and The Board of Trustees of the
2 Leland Stanford Junior University (“Plaintiffs”) hereby allege for their Complaint
3 against SNAC System, Inc. (“Defendant”), on personal knowledge as to their own
4 activities and on information and belief as to the activities of others, as follows:

5 **I. THE PARTIES**

6 1. Plaintiff ThermoLife International, LLC (“ThermoLife”) is a limited
7 liability company organized and existing under the laws of Arizona, with a place of
8 business at 1811 Ocean Front Walk in Venice, California, 90291.

9 2. Plaintiff The Board of Trustees of the Leland Stanford Junior University
10 (“Stanford University”) is an institution of higher education having powers under the
11 laws of the State of California, with a place of business at 1705 El Camino Real in Palo
12 Alto, California, 94306-1106.

13 3. ThermoLife is the exclusive licensee of the following United States
14 Patents:

- 15 a. Patent No. 6,646,006, titled “Enhancement of Vascular Function By
16 Modulation of Endogenous Nitric Oxide Production or Activity”;
17 b. Patent No. 6,117,872, titled “Enhancement of Exercise Performance by
18 Augmenting Endogenous Nitric Oxide Production or Activity”;
19 c. Patent No. 5,891,459, titled “Enhancement of Vascular Function By
20 Modulation of Endogenous Nitric Oxide Production or Activity”; and
21 d. Patent No. 7,452,916, titled “Enhancement of Vascular Function By
22 Modulation of Endogenous Nitric Oxide Production or Activity.”

23 4. The above patents are owned by Stanford University and Thermolife
24 exclusively licenses the patents from Stanford University. ThermoLife is pursuing this
25 action and ThermoLife has the right to join Stanford as a necessary party.

26 5. The above patents are referred to herein as the “patents in suit.”

27 6. Thermolife has been given the right by Stanford University to institute suit
28 with respect to infringement of the patents in suit, including this suit against Defendant.

1 7. Defendant is a corporation organized and existing under the laws of
2 California with a principal place of business at 1551 Industrial Road in San Carlos,
3 California, 94070.

4 **II. JURISDICTION AND VENUE**

5 8. This is an action for patent infringement arising under the patent laws of
6 the United States, Title 35 of the United States Code. Accordingly, this Court has
7 subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338, and 1367.

8 9. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400.

9 10. This Court has personal jurisdiction over Defendant. By way of example
10 and without limitation, Defendant, directly or through intermediaries (including
11 distributors, retailers, and others), makes, manufactures, ships, distributes, advertises,
12 markets, offers for sale, and/or sells dietary supplement products that infringe on one or
13 more claims of the patents in suit (hereinafter the “accused products”), which include
14 without limitation products sold under the “Aerobitine,” “PED,” “Xpedite,” and
15 “Proglycosyn” brand names, in the United States, the State of California, and the
16 Southern District of California.

17 11. By way of further example and without limitation, Defendant has
18 purposefully and voluntarily placed the accused products into the stream of commerce
19 with the expectation that they will be purchased in the Southern District of California,
20 and the products are actually purchased in the Southern District of California.

21 **III. THE DEFENDANT’S INFRINGEMENTS**

22 12. Defendant has committed the tort of patent infringement within the State
23 of California, and more particularly, within the Southern District of California, by
24 virtue of the fact that Defendant has formulated, made, manufactured, shipped,
25 distributed, advertised, offered for sale, and/or sold the accused products in this District,
26 and continues to do so.

27 ///

28 ///

A. DIRECT INFRINGEMENTS

1
2 13. Defendant's employees, agents, representatives and other persons
3 sponsored by or who endorse Defendant and Defendant's products in advertising and
4 marketing activities, have taken, used, and orally administered the accused products.

5 14. The accused products are formulated, made, manufactured, shipped,
6 distributed, advertised, offered for sale, and sold by Defendant to include certain
7 ingredients that, by virtue of their inclusion in the products, infringe one or more claims
8 of one or more of the patents in suit.

9 15. The accused products are formulated, made, manufactured, shipped,
10 distributed, advertised, offered for sale, and sold by Defendant to include specific
11 ingredients for certain purposes that, by virtue of their inclusion in the products for such
12 purposes, infringe one or more claims of one or more of the patents in suit, and as a
13 result, when Defendant's employees, agents, representatives and other persons
14 sponsored by or who endorse Defendant and Defendant's products in advertising and
15 marketing activities orally administer the accused products, they are practicing the
16 methods disclosed in those claims.

17 16. These infringing ingredients, and/or combinations thereof, include, without
18 limitation, L-Arginine, Creatine Monohydrate, L-Citrulline Malate, Folic Acid, and R-
19 Lipoic Acid, as set forth on Defendant's labels for the accused products.

20 17. The purposes for which these ingredients are included in the accused
21 products are, without limitation, to enhance nitric oxide production, to improve nitric
22 oxide activity, to produce nitric oxide, to boost nitric oxide levels in the body, and to
23 enhance physical performance.

24 18. Defendant has encouraged and/or is aware of the fact that its employees,
25 agents, representatives and other persons sponsored by Defendant or who endorse
26 Defendant and Defendant's products in advertising and marketing activities orally
27 administer the accused products and practice the methods disclosed in one or more
28 claim of one or more of the patents in suit, and these employees, agents, representatives

1 and other persons sponsored by Defendant or who endorse Defendant and Defendant's
2 products in advertising and marketing activities are acting under Defendant's direction
3 and control when practicing those methods.

4 19. Therefore, Defendant is a direct infringer of one or more claims of one or
5 more of the patents in suit, and Defendant practices the methods as set forth in one or
6 more claims of one or more of the patents in suit.

7 **B. INDIRECT INFRINGEMENTS**

8 20. End-users of Defendant's accused products are also direct infringers of one
9 or more claims of one or more of the patents in suit.

10 21. End-users of Defendant's accused products have taken, used, and orally
11 administered the accused products.

12 22. The accused products are formulated, made, manufactured, shipped,
13 distributed, advertised, offered for sale, and/or sold by Defendant to include certain
14 ingredients that, by virtue of their inclusion in the products, infringe one or more claims
15 of one or more of the patents in suit.

16 23. The accused products are formulated, made, manufactured, shipped,
17 distributed, advertised, offered for sale, and/or sold by Defendant to include specific
18 ingredients for certain purposes that, because of their inclusion in the products for such
19 purposes, infringe one or more claims of one or more of the patents in suit, and as a
20 result, when end-users of Defendant's accused products orally administer the accused
21 products, they are practicing the methods disclosed in those claims.

22 24. Defendant's labels and advertising for the accused products explain the
23 elements and essential elements of one or more of the methods disclosed in the patents
24 in suit, and those labels and advertising statements encourage, urge, and induce the
25 accused products' end-users to purchase and orally ingest the products to practice those
26 methods, and end-users do practice those methods.

27 ///

28 ///

1 25. Defendant has therefore specifically intended to cause these end-users to
2 directly infringe the claimed methods of these patents, and has in fact urged them to do
3 so.

4 26. The accused products are not suitable for non-infringing uses, and none of
5 Defendant's labels or advertisements for the accused products disclose any uses for the
6 products, nor for the compounds disclosed in the claimed methods of the patents in suit,
7 that do not infringe upon such methods.

8 27. The inclusion of the specific infringing compounds in the products is
9 material to practicing such methods.

10 28. Defendant has knowledge that the accused products are especially adapted
11 by end-users of the products for the practicing of such methods, and, indeed, Defendant
12 encourages, urges, and induces the accused products' end-users to purchase and orally
13 administer the accused products to practice such methods, and has done so in the past.

14 29. Defendant has intentionally and knowingly induced, encouraged, and
15 urged end-users of the accused products to purchase and orally administer the accused
16 products for the purposes of practicing the claimed methods, by having them orally
17 ingest the compounds disclosed in such claims.

18 30. Defendant has knowledge of the fact that the accused products, particularly
19 as administered, infringe on one or more claims of the patents in suit.

20 31. Defendant has direct, firsthand knowledge of the patents in suit.

21 32. For example and without limitation, Defendant has had knowledge of the
22 patents in suit since November 2006, when an ongoing settlement of a patent
23 infringement case relating to at least some of the patents in suit against Herbalife, a
24 well-known company in Defendant's industry, was announced in press releases issued
25 in a highly publicized manner. Defendant's employees, agents, and representatives saw
26 the press releases and were aware of the settlement and thus the patents in suit.

27 33. By way of further example and without limitation, Defendant has sold its
28 products through retailers, including online retailers, and those retailers have sold other

1 companies' products whose labels and/or advertisements have been prominently
2 marked with one or more of the patents in suit, by patent number, including without
3 limitation the products manufactured and sold by Herbalife, Daily Wellness, and
4 Vitality Research Labs. Defendant's employees, agents, and representatives have seen
5 these labels and advertisements and, thus, Defendant has direct knowledge of the
6 patents in suit.

7 34. Defendant has brazenly and willfully decided to infringe the patents in suit
8 despite knowledge of the patents' existence and its knowledge of the accused products'
9 infringements of the patents.

10 35. At a minimum, and in the alternative, Plaintiffs plead that Defendant
11 willfully blinded itself to the infringing nature of the accused products' sales.

12 36. Defendant has not ceased its own direct infringement, nor its contributory
13 infringement or inducement of infringement by end-users, despite its knowledge of the
14 patents in suit and the end-users' infringing activities with respect to the patents in suit.

15 37. Plaintiffs also believe Defendant is infringing on one or more claims of
16 United States Patent No. 5,428,070 and Patent No. 5,945,452, patents which Defendant
17 has had prior knowledge of and are also licensed exclusively to ThermoLife by
18 Stanford University, to include the right to sue for infringement, and Plaintiffs will seek
19 to amend this Complaint once facts confirming that belief are ascertained.

20 **IV. FIRST CAUSE OF ACTION**

21 **Infringement of U.S. Patent No. 6,646,006**

22 38. Plaintiffs repeat and re-allege the allegations of the foregoing paragraphs
23 of this Complaint as if fully set forth herein.

24 39. Defendant has in the past and still is literally and directly infringing or
25 directly infringing under the doctrine of equivalents one or more claims of United
26 States Patent No. 6,646,006 by making, using, selling, and offering for sale the accused
27 products, and will continue to do so unless enjoined by this Court.

28 ///

1 40. In addition to the fact that Defendant makes, uses, sells, and offers for sale
2 the accused products, further examples of Defendant's direct infringements include,
3 without limitation, the fact that Defendant has encouraged and/or is aware of the fact
4 that its employees, agents, representatives and other persons sponsored by or who
5 endorse Defendant and Defendant's products in advertising and marketing activities
6 orally administer the accused products and practice the methods disclosed in one or
7 more claims of United States Patent No. 6,646,006, and these employees, agents,
8 representatives and other persons sponsored by or who endorse Defendant and
9 Defendant's products in advertising and marketing activities are acting under
10 Defendant's direction and control when practicing those methods.

11 41. Defendant has encouraged and is aware of these persons' oral
12 administration of the accused products for these purposes, these persons are acting
13 under Defendant's direction and control, and therefore Defendant is directly practicing
14 the methods disclosed in United States Patent No. 6,646,006.

15 42. End-users of Defendant's accused products are also direct infringers of one
16 or more claims of United States Patent No. 6,646,006.

17 43. End-users of Defendant's accused products have taken, used, and orally
18 administered the accused products.

19 44. The accused products are formulated, made, manufactured, shipped,
20 distributed, advertised, offered for sale, and sold by Defendant to include certain
21 ingredients that, by virtue of their inclusion in the products, infringe one or more claims
22 of United States Patent No. 6,646,006.

23 45. The accused products is formulated, made, manufactured, shipped,
24 distributed, advertised, offered for sale, and sold by Defendant to include specific
25 ingredients for purposes that, by their inclusion in the products for such purposes,
26 infringe one or more claims of United States Patent No. 6,646,006, and as a result,
27 when end-users of Defendant's accused products orally administer the accused
28 products, they are practicing the methods disclosed in one or more claims of that patent.

1 46. Defendant's labels and advertising for the accused products explain the
2 elements and essential elements of the methods disclosed in United States Patent No.
3 6,646,006, and those labels and advertising statements encourage, urge, and induce the
4 accused products' end-users to purchase and orally ingest the products to practice those
5 methods, and end-users do practice those methods.

6 47. Defendant has therefore specifically intended to cause these end-users to
7 directly infringe the claimed methods of United States Patent No. 6,646,006, and has in
8 fact urged them to do so.

9 48. The accused products are not suitable for non-infringing uses, and none of
10 Defendant's labels or advertisements for the accused products disclose any uses for the
11 products, nor for the compounds disclosed in the claimed methods, that do not infringe
12 upon such methods.

13 49. The inclusion of these specific infringing compounds in the products is
14 material to practicing such methods.

15 50. Defendant has knowledge that the accused products are especially adapted
16 by end-users of the products for the practicing of such methods, and, indeed, Defendant
17 encourages, urges, and induces the accused products' end-users to purchase and orally
18 administer the accused products to practice such methods, and have done so in the past.

19 51. Defendant has intentionally and knowingly induced, encouraged, and
20 urged end-users of the accused products to purchase and orally administer the accused
21 products for the purposes disclosed in one or more claims of United States Patent No.
22 6,646,006, by having them orally ingest the compounds disclosed in such claims.

23 52. Defendant has knowledge of the fact that the accused products, particularly
24 as administered, infringe on one or more claims of United States Patent No. 6,646,006.

25 53. Defendant also has direct, firsthand knowledge of United States Patent No.
26 6,646,006.

27 54. Defendant's activities have been without express or implied license by
28 Plaintiffs.

1 under Defendant's direction and control, and therefore Defendant is directly practicing
2 the methods disclosed in United States Patent No. 5,891,459.

3 62. End-users of Defendant's accused products are also direct infringers of one
4 or more claims of United States Patent No. 5,891,459.

5 63. End-users of Defendant's accused products have taken, used, and orally
6 administered the accused products.

7 64. The accused products are formulated, made, manufactured, shipped,
8 distributed, advertised, offered for sale, and sold by Defendant to include certain
9 ingredients that, by virtue of their inclusion in the products, infringe one or more claims
10 of United States Patent No. 5,891,459.

11 65. The accused products is formulated, made, manufactured, shipped,
12 distributed, advertised, offered for sale, and sold by Defendant to include specific
13 ingredients for purposes that, by their inclusion in the products for such purposes,
14 infringe one or more claims of United States Patent No. 5,891,459, and as a result,
15 when end-users of Defendant's accused products orally administer the accused
16 products, they are practicing the methods disclosed in one or more claims of that patent.

17 66. Defendant's labels and advertising for the accused products explain the
18 elements and essential elements of the methods disclosed in United States Patent No.
19 5,891,459, and those labels and advertising statements encourage, urge, and induce the
20 accused products' end-users to purchase and orally ingest the products to practice those
21 methods, and end-users do practice those methods.

22 67. Defendant has therefore specifically intended to cause these end-users to
23 directly infringe the claimed methods of United States Patent No. 5,891,459, and has in
24 fact urged them to do so.

25 68. The accused products are not suitable for non-infringing uses, and none of
26 Defendant's labels or advertisements for the accused products disclose any uses for the
27 products, nor for the compounds disclosed in the claimed methods, that do not infringe
28 upon such methods.

1 69. The inclusion of these specific infringing compounds in the products is
2 material to practicing such methods.

3 70. Defendant has knowledge that the accused products are especially adapted
4 by end-users of the products for the practicing of such methods, and, indeed, Defendant
5 encourages, urges, and induces the accused products' end-users to purchase and orally
6 administer the accused products to practice such methods, and have done so in the past.

7 71. Defendant has intentionally and knowingly induced, encouraged, and
8 urged end-users of the accused products to purchase and orally administer the accused
9 products for the purposes disclosed in one or more claims of United States Patent No.
10 5,891,459, by having them orally ingest the compounds disclosed in such claims.

11 72. Defendant has knowledge of the fact that the accused products, particularly
12 as administered, infringe on one or more claims of United States Patent No. 5,891,459.

13 73. Defendant also has direct, firsthand knowledge of United States Patent No.
14 5,891,459.

15 74. Defendant's activities have been without express or implied license by
16 Plaintiffs.

17 75. As a result of Defendant's acts of infringement, Plaintiffs have suffered
18 and will continue to suffer damages in an amount to be proved at trial.

19 76. As a result of Defendant's acts of infringement, Plaintiffs have been and
20 will continue to be irreparably harmed by Defendant's infringements, which will
21 continue unless Defendant is enjoined by this Court.

22 77. Defendant's past infringements and/or continuing infringements have been
23 deliberate and willful, and this case is therefore an exceptional case, which warrants an
24 award of treble damages and attorneys' fees in accordance with 35 U.S.C. § 285.

25 **VI. THIRD CAUSE OF ACTION**

26 **Infringement of U.S. Patent No. 7,452,916**

27 78. Plaintiffs repeat and re-allege the allegations of the foregoing paragraphs
28 of this Complaint as if fully set forth herein.

1 79. Defendant has in the past and still is literally and directly infringing or
2 directly infringing under the doctrine of equivalents one or more claims of United
3 States Patent No. 7,452,916 by making, using, selling, and offering for sale the accused
4 products, and will continue to do so unless enjoined by this Court.

5 80. In addition to the fact that Defendant makes, uses, sells, and offers for sale
6 the accused products, further examples of Defendant's direct infringements include,
7 without limitation, the fact that Defendant has encouraged and/or is aware of the fact
8 that its employees, agents, representatives and other persons sponsored by or who
9 endorse Defendant and Defendant's products in advertising and marketing activities
10 orally administer the accused products and practice the methods disclosed in one or
11 more claims of United States Patent No. 7,452,916, and these employees, agents,
12 representatives and other persons sponsored by or who endorse Defendant and
13 Defendant's products in advertising and marketing activities are acting under
14 Defendant's direction and control when practicing those methods.

15 81. Defendant has encouraged and is aware of these persons' oral
16 administration of the accused products for these purposes, these persons are acting
17 under Defendant's direction and control, and therefore Defendant is directly practicing
18 the methods disclosed in United States Patent No. 7,452,916.

19 82. End-users of Defendant's accused products are also direct infringers of one
20 or more claims of United States Patent No. 7,452,916.

21 83. End-users of Defendant's accused products have taken, used, and orally
22 administered the accused products.

23 84. The accused products are formulated, made, manufactured, shipped,
24 distributed, advertised, offered for sale, and sold by Defendant to include certain
25 ingredients that, by virtue of their inclusion in the products, infringe one or more claims
26 of United States Patent No. 7,452,916.

27 85. The accused products is formulated, made, manufactured, shipped,
28 distributed, advertised, offered for sale, and sold by Defendant to include specific

1 ingredients for purposes that, by their inclusion in the products for such purposes,
2 infringe one or more claims of United States Patent No. 7,452,916, and as a result,
3 when end-users of Defendant's accused products orally administer the accused
4 products, they are practicing the methods disclosed in one or more claims of that patent.

5 86. Defendant's labels and advertising for the accused products explain the
6 elements and essential elements of the methods disclosed in United States Patent No.
7 7,452,916, and those labels and advertising statements encourage, urge, and induce the
8 accused products' end-users to purchase and orally ingest the products to practice those
9 methods, and end-users do practice those methods.

10 87. Defendant has therefore specifically intended to cause these end-users to
11 directly infringe the claimed methods of United States Patent No. 7,452,916, and has in
12 fact urged them to do so.

13 88. The accused products are not suitable for non-infringing uses, and none of
14 Defendant's labels or advertisements for the accused products disclose any uses for the
15 products, nor for the compounds disclosed in the claimed methods, that do not infringe
16 upon such methods.

17 89. The inclusion of these specific infringing compounds in the products is
18 material to practicing such methods.

19 90. Defendant has knowledge that the accused products are especially adapted
20 by end-users of the products for the practicing of such methods, and, indeed, Defendant
21 encourages, urges, and induces the accused products' end-users to purchase and orally
22 administer the accused products to practice such methods, and have done so in the past.

23 91. Defendant has intentionally and knowingly induced, encouraged, and
24 urged end-users of the accused products to purchase and orally administer the accused
25 products for the purposes disclosed in one or more claims of United States Patent No.
26 7,452,916, by having them orally ingest the compounds disclosed in such claims.

27 92. Defendant has knowledge of the fact that the accused products, particularly
28 as administered, infringe on one or more claims of United States Patent No. 7,452,916.

1 93. Defendant also has direct, firsthand knowledge of United States Patent No.
2 7,452,916.

3 94. Defendant's activities have been without express or implied license by
4 Plaintiffs.

5 95. As a result of Defendant's acts of infringement, Plaintiffs have suffered
6 and will continue to suffer damages in an amount to be proved at trial.

7 96. As a result of Defendant's acts of infringement, Plaintiffs have been and
8 will continue to be irreparably harmed by Defendant's infringements, which will
9 continue unless Defendant is enjoined by this Court.

10 97. Defendant's past infringements and/or continuing infringements have been
11 deliberate and willful, and this case is therefore an exceptional case, which warrants an
12 award of treble damages and attorneys' fees in accordance with 35 U.S.C. § 285.

13 **VII. FOURTH CAUSE OF ACTION**

14 **Infringement of U.S. Patent No. 6,117,872**

15 98. Plaintiffs repeat and re-allege the allegations of the foregoing paragraphs
16 of this Complaint as if fully set forth herein.

17 99. Defendant has in the past and still is literally and directly infringing or
18 directly infringing under the doctrine of equivalents one or more claims of United
19 States Patent No. 6,117,872 by making, using, selling, and offering for sale the accused
20 products, and will continue to do so unless enjoined by this Court.

21 100. In addition to the fact that Defendant makes, uses, sells, and offers for sale
22 the accused products, further examples of Defendant's direct infringements include,
23 without limitation, the fact that Defendant has encouraged and/or is aware of the fact
24 that its employees, agents, representatives and other persons sponsored by or who
25 endorse Defendant and Defendant's products in advertising and marketing activities
26 orally administer the accused products and practice the methods disclosed in one or
27 more claims of United States Patent No. 6,117,872, and these employees, agents,
28 representatives and other persons sponsored by or who endorse Defendant and

1 Defendant's products in advertising and marketing activities are acting under
2 Defendant's direction and control when practicing those methods.

3 101. Defendant has encouraged and is aware of these persons' oral
4 administration of the accused products for these purposes, these persons are acting
5 under Defendant's direction and control, and therefore Defendant is directly practicing
6 the methods disclosed in United States Patent No. 6,117,872.

7 102. End-users of Defendant's accused products are also direct infringers of one
8 or more claims of United States Patent No. 6,117,872.

9 103. End-users of Defendant's accused products have taken, used, and orally
10 administered the accused products.

11 104. The accused products are formulated, made, manufactured, shipped,
12 distributed, advertised, offered for sale, and sold by Defendant to include certain
13 ingredients that, by virtue of their inclusion in the products, infringe one or more claims
14 of United States Patent No. 6,117,872.

15 105. The accused products is formulated, made, manufactured, shipped,
16 distributed, advertised, offered for sale, and sold by Defendant to include specific
17 ingredients for purposes that, by their inclusion in the products for such purposes,
18 infringe one or more claims of United States Patent No. 6,117,872, and as a result,
19 when end-users of Defendant's accused products orally administer the accused
20 products, they are practicing the methods disclosed in one or more claims of that patent.

21 106. Defendant's labels and advertising for the accused products explain the
22 elements and essential elements of the methods disclosed in United States Patent No.
23 6,117,872, and those labels and advertising statements encourage, urge, and induce the
24 accused products' end-users to purchase and orally ingest the products to practice those
25 methods, and end-users do practice those methods.

26 107. Defendant has therefore specifically intended to cause these end-users to
27 directly infringe the claimed methods of United States Patent No. 6,117,872, and has in
28 fact urged them to do so.

1 108. The accused products are not suitable for non-infringing uses, and none of
2 Defendant's labels or advertisements for the accused products disclose any uses for the
3 products, nor for the compounds disclosed in the claimed methods, that do not infringe
4 upon such methods.

5 109. The inclusion of these specific infringing compounds in the products is
6 material to practicing such methods.

7 110. Defendant has knowledge that the accused products are especially adapted
8 by end-users of the products for the practicing of such methods, and, indeed, Defendant
9 encourages, urges, and induces the accused products' end-users to purchase and orally
10 administer the accused products to practice such methods, and have done so in the past.

11 111. Defendant has intentionally and knowingly induced, encouraged, and
12 urged end-users of the accused products to purchase and orally administer the accused
13 products for the purposes disclosed in one or more claims of United States Patent No.
14 6,117,872, by having them orally ingest the compounds disclosed in such claims.

15 112. Defendant has knowledge of the fact that the accused products, particularly
16 as administered, infringe on one or more claims of United States Patent No. 6,117,872.

17 113. Defendant also has direct, firsthand knowledge of United States Patent No.
18 6,117,872.

19 114. Defendant's activities have been without express or implied license by
20 Plaintiffs.

21 115. As a result of Defendant's acts of infringement, Plaintiffs have suffered
22 and will continue to suffer damages in an amount to be proved at trial.

23 116. As a result of Defendant's acts of infringement, Plaintiffs have been and
24 will continue to be irreparably harmed by Defendant's infringements, which will
25 continue unless Defendant is enjoined by this Court.

26 117. Defendant's past infringements and/or continuing infringements have been
27 deliberate and willful, and this case is therefore an exceptional case, which warrants an
28 award of treble damages and attorneys' fees in accordance with 35 U.S.C. § 285.

VIII. PRAYER FOR RELIEF

WHEREFORE, Plaintiffs pray for entry of judgment against Defendant as follows:

1. A declaration that Defendant has infringed the patents in suit, under 35 U.S.C. §§ 271 *et seq.*;

2. That injunctions, preliminary and permanent, be issued by this Court restraining Defendant, its officers, agents, servants, directors, and employees, and all persons in active concert or participation with each, from directly or indirectly infringing, or inducing or contributing to the infringement by others of, the patents in suit;

3. That Defendant be required to provide to Plaintiffs an accounting of all gains, profits, and advantages derived by Defendant's infringement of the patents in suit, and that Plaintiffs be awarded damages adequate to compensate Plaintiffs for the wrongful infringing acts by Defendant, in accordance with 35 U.S.C. § 284;

4. That the damages awarded to Plaintiffs with regard to the patents in suit be increased up to three times, in view of Defendant's willful infringement, in accordance with 35 U.S.C. § 284;

5. That this case be declared to be exceptional in favor of Plaintiffs under 35 U.S.C. § 285, and that Plaintiffs be awarded their reasonable attorneys' fees and other expenses incurred in connection with this action;

6. That Plaintiffs be awarded their interest and costs of suit incurred in this action;

7. Compensatory damages;

8. Punitive damages; and

///

///

///

///

DEMAND FOR JURY TRIAL

Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiffs hereby demand a jury trial for all issues in this case that properly are subject to a jury trial.

Respectfully submitted,

NEWPORT TRIAL GROUP
A Professional Corporation

Dated: February 13, 2014

/s/Tyler J Woods
By: Tyler J. Woods
Attorneys for Plaintiffs

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

CERTIFICATE OF SERVICE

I hereby certify that on February 13, 2014, I electronically filed the foregoing **THERMOLIFE INTERNATIONAL, LLC GROUP, LLC'S AMENDED COMPLAINT FOR PATENT INFRINGEMENT** with the Clerk of the Court using the CM/ECF system which will send notification of such filing via electronic mail to all counsel of record.

/s/Tyler J Woods
Tyler J Woods

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28